SCHEMBL3775591

SCHEMBL3775591

CC(C)(C)OC(=O)N1CCC(Nc2nc(-c3ccccc3F)c3cc(Cl)ccc3n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.48
CNR2 P34972 1/20 0.48
DNMT3A Q9Y6K1 1/20 0.47
CCNT1 O60563 1/20 0.44
IDH1 O75874 1/20 0.44
IDH2 P48735 1/20 0.44
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK8 P45983 2/20 0.42
NSD2 O96028 1/20 0.42
KDM1A O60341 1/20 0.42
EHMT2 Q96KQ7 1/20 0.42
RCOR1 Q9UKL0 1/20 0.42
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774377 0.90 DNMT3A (0.49) CNR1CNR2DNMT3AIDH1IDH2
SCHEMBL3775967 0.78 PIK3CA (0.49) CNR1DNMT3AIDH1IDH2ALDH1A1
SCHEMBL13015076 0.77 CYP1A2 (0.47) MAPTMAPK8PIM1MAPK9MEN1
Hydrochloric Acid SCHEMBL3767830 0.76 CYP1A2 (0.46) MAPTMAPK8PIM1MAPK9MEN1
SCHEMBL25390329 0.74 USP30 (0.59) CNR1CNR2ALDH1A1NPC1MAPT
SCHEMBL9911789 0.73 NSD2 (0.53) CNR1CNR2DNMT3AALDH1A1NPC1
SCHEMBL31334514 0.73 USP30 (0.52) CCNT1IDH1IDH2ALDH1A1MAPK1
SCHEMBL3781169 0.73 SSTR5 (0.53) NSD2KDM1AEHMT2RCOR1
SCHEMBL3775138 0.73 SSTR5 (0.49) NSD2KDM1AEHMT2RCOR1
SCHEMBL29863184 0.73 CNR1 (0.61) CNR1CNR2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
EP-2001867-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 CNR1 144/4885CNR2 164/4885DNMT3A 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.